![Fig. 7. In vivo tracking of BCL1 tumor in peritoneal cavity. / HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and throughout the course of therapy. Mice were then inoculated with 107BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse total). One animal per group was killed each day of therapy, and the percentage tumor cells in the peritoneum was analyzed using 2-color flow cytometry with PE-labeled anti-Id and FITC-labeled anti-CD22. In mice treated with [huCD64 × Id] BsAb, tumor cells were detected using FITC-labeled anti-CD22 and PE-labeled anti-CD19 (see “Materials and methods”). The graph shows the percentage of tumor cells in the peritoneal cavity present on each day of therapy after treatment with PBS (●), [huCD64 × Id] BsAb (○), [huCD64 × MHC II] BsAb (■), or [huCD64 × CD19] BsAb (▵). Symbols on plots show BsAb specificity. The inset shows scatter profiles of tumor (gated) on day 5, from mice receiving control PBS (top) or anti-MHC II BsAb (bottom). Similar results were obtained in at least 2 similar experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347007.jpeg?Expires=1725294417&Signature=mXjE8gt1S0xoLj0vUjA1S7hPdCQmizJArISlAUKI7ASrYsHyPc45M5SnD8te-1Zbw~2IaRFVTwalh9KLw7KXemkv2DZPCogs5lnwmXt1gfVopkTHBU~uvNDWpU6IGxVAUYyTOdM-jf~6F6GbRnL91Iak7PlL6DV7Qy6IQMy360-UYEH1FBr0pq35IKm8rtFwazgUq-~RwrP35PZzJRqZIf9o4r~2M1NsbeczSgvK-2YOG-rVNVLY3wfFo5HCgNpviBU69RhxZnc1r-Y3AjQ1YYnHXjqKd~Mks9SzOiJ9cYpUbuxcre7k9-KPUJGDxljoAAlrzqdgQ6g8U~YP7GUtrA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vivo tracking of BCL1 tumor in peritoneal cavity.
HuCD64+ mice received 2 μg murine G-CSF/d subcutaneously 4 days before tumor and throughout the course of therapy. Mice were then inoculated with 107BCL1 tumor cells intraperitoneally on day 0 and were treated with twice daily injections of 50 μg BsAb intraperitoneally on days 1 to 5 (500 μg/mouse total). One animal per group was killed each day of therapy, and the percentage tumor cells in the peritoneum was analyzed using 2-color flow cytometry with PE-labeled anti-Id and FITC-labeled anti-CD22. In mice treated with [huCD64 × Id] BsAb, tumor cells were detected using FITC-labeled anti-CD22 and PE-labeled anti-CD19 (see “Materials and methods”). The graph shows the percentage of tumor cells in the peritoneal cavity present on each day of therapy after treatment with PBS (●), [huCD64 × Id] BsAb (○), [huCD64 × MHC II] BsAb (■), or [huCD64 × CD19] BsAb (▵). Symbols on plots show BsAb specificity. The inset shows scatter profiles of tumor (gated) on day 5, from mice receiving control PBS (top) or anti-MHC II BsAb (bottom). Similar results were obtained in at least 2 similar experiments.
